Novo Nordisk expands manufacturing facility in US
Novo Nordisk has opened its US$100m, 200,000 ft2 expanded facility in Clayton, North Carolina, to meet the country\'s increasing demand for FlexPen prefilled insulin pen.
Novo Nordisk has opened its US$100m, 200,000 ft2 expanded facility in Clayton, North Carolina, to meet the country's increasing demand for FlexPen prefilled insulin pen.
The event marked the second expansion in three years of the company's only insulin manufacturing facility in the US, doubling the company's domestic insulin filling capabilities and initiating the first domestic production of FlexPen.
As a result, more than 50 jobs have been created. To date, Novo Nordisk has expanded its workforce in Clayton to 400.
Approximately 54 million Americans have pre-diabetes, a condition that puts them at increased risk for diabetes, a chronic disease affecting nearly 21 million Americans.
